Advanced Solid Tumor
Conditions
Brief summary
This is a Phase 1, single-arm, open-label, dose-escalation study in patients with advanced solid tumors including 2 parts: Part 1: Dose-Escalation Part Part 2: Dose-Expansion Part
Detailed description
Part 1: Patients with advanced solid tumors that has relapsed from or is refractory to standard therapy or for which no standard therapy exists will be enrolled in different cohorts. Part 2: Recommended Phase 2 dose (RP2D) of NWY001 will be given to all patients enrolled in this part.
Interventions
BIOLOGICALNWY001
Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
Sponsors
Chipscreen Biosciences, Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Willingness to sign a written informed consent document 2. Participant with advanced solid malignant tumor that has relapsed from or is refractory to standard therapy or for which no standard therapy exists 3. 18\ 75 years of age at the time of screening 4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 5. Life expectancy ≥3 months 6. Laboratory tests meet the following criteria (no corrective treatment, such as G-CSF, erythropoietin, and blood transfusion, within 14 days before first dose): 1\) absolute neutrophil count (ANC) ≥1.5×109/L 2) platelet ≥100×109/L 3) hemoglobin ≥90 g/L 4) creatinine clearance \>50 mL/min (according to Cockcroft-Gault equation) 5) both alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤1.5×upper limit of normal (ULN) (≤5×ULN for patients with hepatic metastasis) 6) total bilirubin ≤1.5×ULN (≤3×ULN for patients with gilbert syndrome) 7) international normalized ratio (INR) \<2.0, activated partial thromboplastin time (aPTT) ≤1.5×ULN 7\. Prior anti-cancer therapy meets the following criteria: 1. major surgery ≥4 weeks 2. radiotherapy ≥4 weeks 3. endocrine therapy ≥2 weeks 4. chemotherapy (including antibody) ≥3 weeks 5. immunotherapy ≥4 weeks 8\. At least one measurable target lesion as defined by RECIST1.1 9\. For part 2a: Participant has a diagnosis of histologically confirmed advanced (unresectable) or metastatic gastric or gastroesophageal junction adenocarcinoma 1. participant with HER2 overexpression (IHC 3+ or IHC 2+/ISH+) is refractory or intolerant to standard therapy or for which no standard therapy exists. Prior treatment with trastuzumab or HER2-targeted drugs 2. participant with no HER2 expression is refractory or intolerant to standard therapy or for which no standard therapy exists 10\. For part 2b: Participant has a diagnosis of histologically confirmed advanced esophageal squamous carcinoma 11\. For part 2c: Participant has a diagnosis of histologically confirmed advanced pancreatic ductal adenocarcinoma 12\. For part 2d: Participant has a diagnosis of histologically confirmed advanced hepatocellular carcinoma 13\. For part 2e: Participant has a diagnosis of histologically confirmed advanced intrahepatic cholangiocarcinoma 14\. For part 2f: Participant has a diagnosis of histologically confirmed advanced MSI-H/dMMR colorectal cancer
Exclusion criteria
1\. Current or previous history of other active aggressive malignancies in the last 5 years, except : 1. previous history of non-aggressive malignancies, such as cervical carcinoma in situ, melanoma in situ, or ductal carcinoma in situ of the breast that remains in complete remission for years after curative treatment 2. malignancies with negligible risk of metastasis or death (such as adequately treated basal or squamous cell skin cancer and focal prostate cancer) 2\. Current or previous history of hematological malignancies 3\. Primary central nervous system (CNS) malignancies or CNS metastases 4\. History of allergy or hypersensitivity to monoclonal antibodies or excipients, or a known history of allergy to antibodies produced by Chinese hamster ovary cell 5\. Uncontrolled infection that requires intravenous antibiotics, antivirals, or antifungal medications 6\. History of clinically significant lung diseases (such as interstitial pneumonia, pneumonia, pulmonary fibrosis, and severe radiation pneumonia), or patients suspected of having these diseases on radiographic examination during the screening period 7\. Uncontrolled complications, including, but not limited to, persistent active infections, active coagulopathy, uncontrolled cardiovascular disease, uncontrolled immune disease, uncontrolled diabetes, uncontrolled chest and abdominal fluid accumulation, psychiatric disorders that do not meet study requirements, and other serious conditions requiring systemic treatment 8\. Known history of HIV, active infections of hepatitis B or hepatitis C 9\. Active pulmonary tuberculosis. Participants vaccinated with BCG vaccine may be false positive for PPD, and they could be enrolled if negative for IGRA 10\. Women who are pregnant or breastfeeding or intended to become pregnant during the study period 11\. Participants of childbearing potential who refuse to take highly effective contraceptive measures during the entire study treatment period and for 120 days after the last dose of study drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dose-limiting toxicity (DLT) | Up to 21 days | Number of patients experienced any dose limited toxicity |
| Incidence of adverse events (AEs) | Until 30 days after the last dose of the study drug | Number of patients experienced AEs |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | Until 30 days after the last dose of the study drug | Time to progression as assessed by the Investigator at local site per RECIST 1.1, or death due to any cause |
| Maximum plasma concentration (Cmax) | From pre-dose to 30 days after the last dose of the study drug | Pharmacokinetic profile of NWY001 |
| Time to Cmax (Tmax) | From pre-dose to 30 days after the last dose of the study drug | Pharmacokinetic profile of NWY001 |
| Area under the plasma concentration-time curve from 0 to infinity (AUC 0-inf) | From pre-dose to 30 days after the last dose of the study drug | Pharmacokinetic profile of NWY001 |
| Objective response rate (ORR) | Until 30 days after the last dose of the study drug | The proportion of patients who have a complete response (CR) or partial response (PR), as determined by the Investigator at local site per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 |
| Interleukin-6 (IL-6) | From pre-dose to 30 days after the last dose of the study drug | Pharmacodynamic profile of NWY001 |
| Incidence of anti-drug antibody (ADA) | From pre-dose to 30 days after the last dose of the study drug | Immunogenicity of NWY001 |
| Incidence of neutralizing antibody (NAb) | From pre-dose to 30 days after the last dose of the study drug | Immunogenicity of NWY001 |
| Tumor necrosis factor-α (TNF-α) | From pre-dose to 30 days after the last dose of the study drug | Pharmacodynamic profile of NWY001 |
| Disease control rate (DCR) | Until 30 days after the last dose of the study drug | The proportion of patients who have a CR or PR or stable disease (SD), as determined by the Investigator at local site per RECIST 1.1 |
Countries
China
Contacts
Primary ContactXinhao Wang
Outcome results
None listed